Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2004

01-03-2004 | Image of the Month

Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with 68Ga-DOTATOC PET

Authors: Marcus Henze, Jochen Schuhmacher, Antonia Dimitrakopoulou-Strauss, Ludwig G. Strauss, Helmut R. Mäcke, Michael Eisenhut, Uwe Haberkorn

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2004

Login to get access

Excerpt

The preparation and application of 68Ga-DOTATOC for PET imaging of somatostatin receptors was initially described in meningiomas [1] and neuroendocrine tumours [2, 3]. In the presented patient, extremely high tumoural uptake of 68Ga-DOTATOC was detected. The mean SUV in the pancreatic tumour was 166.4 (maximum 199.2). This was much higher even than the uptake in the normal spleen, which is the organ with the highest physiological DOTATOC uptake (mean 26.2, maximum 33.1). Mean SUV in normal tissues was as follows: kidneys, 10.7 ( maximum 13.8); liver, 6.2 (maximum 7.4); pancreas, 3.1 (maximum 4.9); muscle, 0.9 (maximum 1.9); and lung, 0.7 (maximum 1.1). …
Literature
1.
Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker D, Doll J, Mäcke H, Hofmann M, Debus J, Haberkorn U. PET imaging of somatostatin receptors using [68Ga]-DOTA-d Phe1-Tyr3-octreotide (DOTATOC): first results in meningioma patients. J Nucl Med 2001; 42:1053–1056.PubMed
2.
HofmannM, MaeckeH, Börner AR, Weckesser E, Schöffski P, Oei ML, Schumacher J, Henze M, Heppeler A, Meyer GJ, Knapp WH. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28:1751–1757.PubMed
3.
Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using68Ga-DOTA-d Phe(1)-Tyr(3)-octreotide in comparison to 111In-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003; 5:42–48.
Metadata
Title
Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with 68Ga-DOTATOC PET
Authors
Marcus Henze
Jochen Schuhmacher
Antonia Dimitrakopoulou-Strauss
Ludwig G. Strauss
Helmut R. Mäcke
Michael Eisenhut
Uwe Haberkorn
Publication date
01-03-2004
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1436-2

Other articles of this Issue 3/2004

European Journal of Nuclear Medicine and Molecular Imaging 3/2004 Go to the issue

Original Article

Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?

News & Views

March 2004

Original Article

Application of statistical parametric mapping to SPET in the assessment of intractable childhood epilepsy

Review Article

Highlights of the Annual Congress of the European Association of Nuclear Medicine, Amsterdam 2003

Original Article

FDG-PET/CT in re-staging of patients with lymphoma

Molecular Imaging

Feasibility of sodium/iodide symporter gene as a new imaging reporter gene: comparison with HSV1-tk